← Leaderboards
Rolf F Kletzien
Metabolic Solutions Development Co
$1,480,534
Attributed
$2,820,156
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2009–14$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
'14
Funding mix
By agency
NIH$2,820,156 · 4
By mechanism
R42$2,557,289 · 2
R41$140,911 · 1
R43$121,956 · 1
Top collaborators
- Brian N Finck3 shared
- Anne N Murphy3 shared
- Jerry Raymond Colca1 shared
Most similar at Metabolic Solutions Development Co
Same institution · by research overlap
- Jerry Raymond Colca$60,978
Others in their field
Top investigators on “Receptor”
- Barton F Haynes · Duke University$182,835,224
- James C. Paulson · Scripps Research Institute$84,068,192
- Asrar B. Malik · University Of Illinois At Chicago$55,280,031
- Anthony O Caggiano · Cognition Therapeutics, Inc.$49,563,751
- Robert J Coffey · Vanderbilt University$48,115,270
- Robert H Vonderheide · University Of Pennsylvania$48,030,034
Research focus
ReceptorApplications GrantsPre-ClinicalThiazolidinedionesBase2,4-ThiazolidinedioneMetabolicPharmacologySolutionsNon-Insulin-Dependent Diabetes MellitusPeroxisome Proliferator-Activated ReceptorsDiabetes MellitusInsulinFoundationsCellsAdverse EffectsInsulin Sensitizing DrugsDoseIncidenceBiological AvailabilityAnalogCardiovascular SystemBinding (Molecular Function)Acute
Grant awards (8)
Therapeutic Use of mTOT Modulators in Polycystic Kidney Disease$121,956
R43 · FY2014 · DK · contact PI
Evaluation of PPARgam-sparing TZDs for Treating Non-Alcoholic Fatty Liver Disease$560,998
R42 · FY2012 · AA · contact PI
Evaluation of PPARgam-sparing TZDs for Treating Non-Alcoholic Fatty Liver Disease$50,000
R42 · FY2012 · AA · contact PI
PPAR-sparing/free Thiazolidinediones for Treatment of Diabetes$634,311
R42 · FY2011 · DK · contact PI
Evaluation of PPARgam-sparing TZDs for Treating Non-Alcoholic Fatty Liver Disease$563,804
R42 · FY2011 · AA · contact PI
PPAR-sparing/free Thiazolidinediones for Treatment of Diabetes$608,312
R42 · FY2010 · DK · contact PI
Evaluation of PPARgam-sparing TZDs for Treating Non-Alcoholic Fatty Liver Disease$140,911
R41 · FY2009 · DK · contact PI
PPAR-sparing/free Thiazolidinediones for Treatment of Diabetes$139,864
R42 · FY2009 · DK · contact PI